Virax Biolabs

VRAX

市值 US$116萬

Fiscal 2026 Annual Report, filed July 2, 2026, reflects cash of $6.4 million, total assets of $8.3 million and shareholders' equity attributable to ordinary shareholders of $7.3 million Fosun Diagnostics agreement, announced July 9, 2026, supports commercial execution for ImmuneSelect across six Southeast Asian markets Preferred investment option exercise, completed July 10, 2026, generated approximately $3.3 million in gross proceeds, further strengthening the Company's liquidity position and balance sheet Nasdaq confirmed on July 13, 2026, that the Company regained compliance with the minimum bid price requirement LONDON, July 16, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), a biotechnology company focused on immune response detection, T cell immune profiling and in vitro diagnostic technologies, today published a shareholder update from Chief Executive Officer James Foster providing context on the Company's fiscal 2026 Annual Report and subsequent commercial, financing and Nasdaq compliance developments. The Annual Report provides audited financial statements for fiscal year 2026, updates shareholders on the Company's strategic focus, and reflects the Company's recently completed 1-for-25 share consolidation.

LONDON, July 10, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX) today closed its previously announced exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value $0.025 (the "Ordinary Shares") originally issued in October 2023 (as amended in December 2025) and in December 2025 having an original exercise price of $10.00 per share, at a reduced exercise price of $6.00 per share. The resale of the Ordinary Shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (Nos.

LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX) announced today that it has entered into a definitive agreement for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value $0.025 (the "Ordinary Shares") originally issued in October 2023 (as amended in December 2025) and in December 2025 having an original exercise price of $10.00 per share, at a reduced exercise price of $6.00 per share.  The resale of the Ordinary Shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (Nos.

Virax Biolabs (VRAX) shares exploded higher on Thursday morning after management announced a lucrative cross-border commercial breakthrough. In a press release dated July 9th, the company said its UK subsidiary signed an “exclusive” multi-country commercial supply agreement with Fosun Diagnostics, a key division of Shanghai Fosun Pharmaceutical.

Virax Biolabs Group Limited (NASDAQ:VRAX) stock is up during Thursday's premarket session, as the company has signed a multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line, which is aimed at immune profiling.

LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the Company's ImmuneSelect research-use immune profiling product line. The agreement covers six Southeast Asian markets, including Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, and establishes a framework for immediate product supply under purchase orders, supporting near-term potential revenue opportunities and regional commercial expansion.

LONDON, June 24, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that the board of directors of the Company approved a share consolidation of the Company's authorized, issued and outstanding ordinary shares of US$0.001 par value each at a ratio of 1-for-25 effective 26 June 2026 (the "Share Consolidation"). The shareholders approved the Share Consolidation at the adjourned extraordinary general meeting of the shareholders held on Friday, June 12, 2026, at 2.00 p.m.

LONDON, May 26, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS"). In the pilot dataset, ViraxImmune™ demonstrated measurable separation between PAIS patients and healthy controls, achieving 88% specificity and 92% positive predictive value ("PPV") — early performance metrics that Virax believes support continued development and advancement into larger clinical validation.

Virax Biolabs is advancing a focused strategy centered on ViraxImmune™ and a U.S. market-entry pathway, which management believes is not reflected in the Company's current public valuation despite its balance sheet strength, debt-free position, recent financing and operational progress. LONDON, April 14, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immunology research and diagnostics, today published a shareholder letter from Chief Executive Officer James Foster and released an updated investor presentation.

Virax Biolabs said that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, a risk management company based in the United Kingdom.